Categories: BusinessDevelopmentDrugEnterprisePlatformResearch
Alivexis is dedicated to fostering healthier and more fulfilling lives by integrating cutting-edge drug discovery platforms, profound understanding of disease biology, and agile global business operations.
Investors 2
Mentions in press and media 1
| Date | Title | Description |
| 24.06.2024 | Melodia Therapeutics launched with in-licensing deal |
MDI-0151 is a clinical candidate compound from the Alivexis’ discovery program MOD-A, focused on Cathepsin C inhibition. Cathepsin C is an enzyme responsible for the activation of a group of proteases that play an important role in the des... |
Reviews 0
